| | | October 30, 2023 Hey traders! It's Michael here with the Stock Dork Cheat Sheet: Premarket Report, your go-to guide for the day's biggest trading news and hottest premarket stocks! Happy Monday! It's October 30th. I hope you had a great weekend. Now, let's get ready to trade! |
| Stocks closed last week with more losses for U.S. indexes. The Nasdaq was the day's lone gainer with a 0.3% loss, while the Dow sold off for 1.1% and the S&P 500 lost 0.4%. The small-cap Russell 2K also suffered a steep 1.2% sell-off. Today, futures are rebounding in early-morning trading. Dow and S&P 500 contracts are both up 0.6%, so we're likely headed for a higher open. Exec Aims for 111,000% Gains.... Again! 🚀 After a huge 111,000% success in Monster Energy, this CEO is jumping on the health trend with a drink that has no added sugar and is 100% plant-based. The energy drink industry is growing at an over 7% CAGR and most of the market is dominated by unhealthy options. Now investors are presented with a healthy alternative in a sector that is set to explode past $86B. It could be a game-changer that puts this tiny, under-the-radar stock on the map with the Smart Money. Get all the Details Here ⚪ NoneQuiet start to the week with some earnings data moving the premarket, and there are also some new updates on the China property market. For the most part, it's pretty quiet. |
| BorgWarner [BWA] - Last Close: $36.68 BorgWarner is trending after closing last week with losses. The automobile parts & solutions stock fell 4.1% on Friday despite no obvious news to explain the move. However, shares are rebounding in today's premarket, once again without any kind of obvious catalyst. Several analysts cut their price target on BWA this month, and the stock has been in a slow downtrend since the start of October. However, BWA is leading the S&P 500 this morning with a 9.6% gain. My Take: BWA's close relationship with the automobile sector may explain some of its recent volatility. Bearish forecasts from major U.S. automakers could be souring sentiment on this stock, despite the lack of company-specific news. Aaron's Company [AAN] - Last Close: $7.22 Aaron's is rebounding after a rough row. Last week, the rent-to-buy company reported weaker-than-expected fiscal 2023 results that fell short of Wall Street's expectations, and a sell-off followed. Aaron's sales declined by 11.4% YoY to $525.68 million for the year, and missed the Street's $536.1 million target. The company's adjusted EPS also missed the market, although its overall operating loss narrowed compared to last year. Shares of AAN are down 21.9% as a result of its post-earnings sell-off, but shares are rebounding in today's premarket. AAN is up 22.1%, despite no company specific news. My Take: AAN appears to be undergoing a natural correction after last week's potentially-overdone sell-off. This stock has some appealing aspects to it, and we could see the downward move bottom out soon. I'm watching this one. Miromatrix Medical [MIRO] - Last Close: $1.04 A buyout deal is boosting shares of Miromatrix Medical. Today, the company announced it has agreed to be acquired by United Therepeutics [UTHR] in an all-cash $91 million deal. MIRO investors will receive $3.25 per share on close, plus an additional milestone payment of $1.75 tied to mirokidney™'s clinical progress. The transaction is expected to close in the fourth quarter of 2024, subject to shareholder approval and customary closing conditions. MIRO is today's top premarket stock with a 225.0% gain. My Take: MIRO landed one hell of a deal here, but the upside is all but gone. At this point, you'd be getting in with the hopes the milestone payment is achieved, but there's no guarantee it will come through. VYNE Therapeutics [VYNE] - Last Close: $2.25 VYNE Therapeutics is up on the heels of a promising clinical update. The NJ-based biopharma firm said preclinical models for its oral BD2-Selective BET inhibitor VYN202 showed positive effects in psoriasis & arthritis patients. CEO David Domzalski said, "These compelling preclinical data in skin inflammation and joint disease models highlight VYN202’s potential for therapeutic utility..." VYNE will host an R&D Day event on Thursday, November 9, 2023, at 1:30 p.m. ET, and it's planning to submit an IND to the FDA by year-end. VYNE is one of this morning's top movers with a 44.3% gain. My Take: Looks like VYNE is onto a promising drug here. Arthritis and psoriasis are both relatively common, so there could be a huge market for this drug if approved. This long-shot could be worth watching. GainersConduit Pharma [CDT] >> +61.7%Motus GI [MOTS] >> +31.9%Coherus BioScience [CHRS] >> +18.5% DeclinersBIO-Key [BKYI] >> (27.2%) Laird Superfood [LSF] >> (23.6%)Forbion European [FRBN] >> (19.1%) McDonald's Corporation [MCD] ... AM
On Semiconductor Corporation [ON] ... AM
Check Point Software Technologies [CHKP] ... AM
Arista Networks [ANET] ... PM
Welltower [WELL] ... PM
Public Storage [PSA] ... PM
Simon Property Group [SPG] ... PM
Arch Capital Group [ACGI] ... PM
Monolithic Power Systems [MPWR] ... PM
Pinterest [PINS] ... PM None |
| Thanks for reading! Don't forget, I'm always eager to hear from you. Reply to this email with your questions, comments, or general feedback, and I'll get back to you as soon as I can. Wishing you big returns on your investments this week, as always! - Michael "The Stock Dork" Taylor Disclaimer© 2023 TheStockDork.com. All rights reserved. This message was sent by TheStockDork.com and may contain commercial elements such as advertising. Read full terms here. |
|
|
|
| | |
|
